Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 7/20 | 0.38 |
| ▸ | CA2 | P00918 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.38 |
| ▸ | CA9 | Q16790 | 6/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.37 |
| ▸ | CA4 | P22748 | 3/20 | 0.37 |
| ▸ | CA6 | P23280 | 3/20 | 0.37 |
| ▸ | CA5A | P35218 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 3/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989588 | 0.80 | CYP3A4 (0.50) | CYP3A4TSHRALDH1A1NFE2L2SLC40A1 | |
| SCHEMBL17647899 | 0.80 | NOS3 (0.43) | TSHRCA1CA2CA9CA12 | |
| SCHEMBL9179403 | 0.78 | TSHR (0.43) | CYP3A4TSHRALDH1A1NFE2L2 | |
| SCHEMBL845336 | 0.78 | CYP3A4 (0.43) | CYP3A4TSHRALDH1A1NFE2L2 | |
| Ammonia Solution, Strong SCHEMBL28206444 | 0.78 | NOS3 (0.41) | TSHRCA1CA2CA9CA12 | |
| SCHEMBL9174593 | 0.77 | NFE2L2 (0.44) | CYP3A4TSHRALDH1A1NFE2L2SLC40A1 | |
| SCHEMBL9176169 | 0.77 | TSHR (0.42) | CYP3A4TSHRALDH1A1NFE2L2 | |
| Potassium Ion SCHEMBL9175274 | 0.77 | NFE2L2 (0.44) | CYP3A4TSHRALDH1A1NFE2L2SLC40A1 | |
| SCHEMBL9174597 | 0.77 | TSHR (0.42) | CYP3A4TSHRALDH1A1NFE2L2 | |
| Lithium Ion SCHEMBL9176164 | 0.77 | NFE2L2 (0.44) | CYP3A4TSHRALDH1A1NFE2L2SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH HOLDINGS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| CN-1550496-A | Acetylenic alpha-amino acid-based sulfamide hydroxamic acid TACE inhibitors | ���Ͽع�����˾ | 2004-12-01 | — | — | CN | disclosed |
| US-6812227-B2 | SULFUR COMPOUNDS SUCH AS 2-((4-BUT-2-YNYLOXY-BENZENESULFONYL)-METHYL-AMINO)-N-HYDROXY-3-METHYL -BUTYRAMIDE, USED AS TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) INHIBITORS, FOR PROPHYLAXIS OF RHEUMATIC DISEASES, SEPSIS OR INFLAMMATION | WYETH HOLDINGS CORPORATION | 2004-11-02 | — | — | US | disclosed |
| EP-1144368-B1 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6716833-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE AND DEGENERATIVE CARTILAGE LOSS. | WYETH HOLDINGS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | disclosed |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | disclosed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | disclosed |
| CN-1345308-A | Acetylenic alpha-amino acid based sulfonamide hydroxamic acid TACE inhibitors | AMERICAN CYANAMID CO (US) | 2002-04-17 | — | — | CN | disclosed |
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | CYP3A4 3340/4885TSHR 3457/4885CA1 53/4885 |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | CYP3A4 3340/4885TSHR 3457/4885CA1 53/4885 |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | CYP3A4 3340/4885TSHR 3457/4885CA1 53/4885 |
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, MMP12 | CYP3A4 3646/4885TSHR 3185/4885CA1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.